STAT3 and Miyoshi myopathy: Aside from the possibility that STAT3 Y705 could represent a candidate pharmacodynamic biomarker of ATR inhibitor activity in this disease, it is conceivable that MM cells with high basal STAT3 activity, and presumably dependent upon this transcription factor for survival, may be particularly susceptible to ATR inhibitor-based strategies.